Search Results - "Dupuis, O"

Obstetrical and neonatal complications in hereditary haemorrhagic telangiectasia: Clarifications on fetal outcomes by Delagrange, L., Dupuis, O., Dupuis‐Girod, S.

Get full text

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer by Azria, D., Doyen, J., Jarlier, M., Martel-Lafay, I., Hennequin, C., Etienne, P., Vendrely, V., François, E., de La Roche, G., Bouché, O., Mirabel, X., Denis, B., Mineur, L., Berdah, J., Mahé, M., Bécouarn, Y., Dupuis, O., Lledo, G., Seitz, J., Bedenne, L., Gourgou-Bourgade, S., Juzyna, B., Conroy, T., Gérard, J.

“…Outcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The…”
Get full text

Obstetric intensive care unit admission: a 2-year nationwide population-based cohort study by Zwart, Joost J., Dupuis, Just R. O., Richters, Annemiek, Öry, Ferko, van Roosmalen, Jos

“…Purpose As part of a larger nationwide enquiry into severe maternal morbidity, our aim was to assess the incidence and possible risk factors of obstetric…”
Get full text

Postpartum haemorrhage and postpartum urinary retention: could voiding be the best way of avoiding postpartum haemorrhage? by Dupuis, O

Get full text

I104 COMPUTERISED TRAINING, LABOUR AND BIRTH by Dupuis, O.

Get full text

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial by Bachet, J.B., Lucidarme, O., Levache, C.B., Barbier, E., Raoul, J.L., Lecomte, T., Desauw, C., Brocard, F., Pernot, S., Breysacher, G., Lagasse, J.P., Di Fiore, F., Etienne, P.L., Dupuis, O.J.M., Aleba, A., Lepage, C., Taieb, J., Dahan, L., Auby, D., Khemissa, F., Ghiringhelli, F., Nguyen, S., Bedjaoui, A., Terrebonne, E., Thaury, J., Baconnier, M.

“…The optimal therapeutic strategy in patients with rectal cancer and synchronous unresectable metastases remains unknown. We evaluated the efficacy of…”
Get full text

Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors by Al Tabosh, T., Liu, H., Koça, D., Al Tarrass, M., Tu, L., Giraud, S., Delagrange, L., Beaudoin, M., Rivière, S., Grobost, V., Rondeau-Lutz, M., Dupuis, O., Ricard, N., Tillet, E., Machillot, P., Salomon, A., Picart, C., Battail, C., Dupuis-Girod, S., Guignabert, C., Desroches-Castan, A., Bailly, S.

“…Heterozygous activin receptor-like kinase 1 ( ALK1 ) mutations are associated with two vascular diseases: hereditary hemorrhagic telangiectasia (HHT) and more…”
Get full text

The European Rare Disease Network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care by Shovlin, C.L., Buscarini, E., Sabbà, C., Mager, H.J., Kjeldsen, A.D., Pagella, F., Sure, U., Ugolini, S., Torring, P.M., Suppressa, P., Rennie, C., Post, M.C., Patel, M.C., Nielsen, T.H., Manfredi, G., Lenato, G.M., Lefroy, D., Kariholu, U., Jones, B., Fialla, A.D., Eker, O.F., Dupuis, O., Droege, F., Coote, N., Boccardi, E., Alsafi, A., Alicante, S., Dupuis-Girod, S.

“…Hereditary haemorrhagic telangiectasia (HHT) is a complex, multisystemic vascular dysplasia affecting approximately 85,000 European Citizens. In 2016, eight…”
Get full text

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study by Bourgeois, H., Grudé, F., Solal-Céligny, P., Dupuis, O., Voog, E., Ganem, G., Denis, F., Zinger, M., Juhel-Voog, L., Lafond, C., Maillart, P., Capitain, O., Delva, R., Soulié, P., Abadie-Lacourtoisie, S., Guérin-Meyer, V., Morin-Meschin, M.E., Commer, J.M., Gangler, A., d’Aillières, B., Zannetti, A., Bourbouloux, E., Berton-Rigault, D., Lebouvier-Sadot, S., Kaassis, M., Baudon, J., Lam, Y.H., Bizieux, A., Marcq, M., Edeline, J., Le Du, F., Lefeuvre, C., Deguiral, P., Delecroix, V., Blot, E., Egreteau, J., Goudier, M.J., Lamy, R., Ferec, M., Artignan, X., Corbinais, S., Morel, H., Hardy-Bessard, A.C., Alleaume, C., Naudeix, E., Cojocarasu, O., Metges, J.P., Riché, C., Gamelin, E., Déniel-Lagadec, D., Marhuenda, F., Ingrand, P., Douillard, J.Y.

“…In 2008, a study of the characteristics of hospitalised patients led to the development of a prognostic tool that distinguished three populations with…”
Get full text

Heterogeneity of pregnancy outcomes and risk of LGA neonates in Caucasian females according to IADPSG criteria for gestational diabetes mellitus by Disse, E, Graeppi-Dulac, J, Joncour-Mills, G, Dupuis, O, Thivolet, C

“…Abstract Objective The International Association of Diabetes and Pregnancy Study Group (IADPSG) guidelines for gestational diabetes mellitus (GDM) diagnosis…”
Get full text

Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial by Delbaldo, C., Ychou, M., Zawadi, A., Douillard, J.Y., André, T., Guerin-Meyer, V., Rougier, P., Dupuis, O., Faroux, R., Jouhaud, A., Quinaux, E., Buyse, M., Piedbois, P.

“…The R98 trial explores the addition of irinotecan to a 5-fluorouracil (5-FU) plus leucovorin (5-FU/LV) adjuvant regimen in optimally resected stages II–III…”
Get full text

Concurrent Chemoradiation Therapy Versus Acceleration of Radiation Therapy With or Without Concurrent Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): 7-Year Survival Data From a Phase 3 Randomized Trial and Prognostic Factors by TAO, Y, Aupérin, A, Graff, P, Gregoire, V.G, Maingon, P, Calais, G, Gery, B, Martin, L, Alfonsi, M, Desprez, P, Bardet, E, Rives, M, Geoffrois, L, Tuchais, C, Dupuis, O, Guerif, S, Lapeyre, M, Sire, C, Bourhis, J

Get full text

OC-7b: Implementation of risk score-guided prophylaxis in over 2000 pregnant women at risk of thrombotic events: impact on morbidity. A quasi-experimental prospective study by Chauleur, C, Gris, J.-C, Laporte, S, Chapelle, C, Equy, V, Gaucherand, P, Bazan, E, Dupuis, O, Buchmüller, A, Gallot, D

Get full text

Are third-trimester adipokines associated with higher metabolic risk among women with gestational diabetes? by Honnorat, D, Disse, E, Millot, L, Mathiotte, E, Claret, M, Charrie, A, Drai, J, Garnier, L, Maurice, C, Durand, E, Simon, C, Dupuis, O, Thivolet, C

“…Abstract Aim This study aimed to determine whether third-trimester adipokines during gestational diabetes (GDM) are associated with higher metabolic risk…”
Get full text

P-136Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients by Metges, J-P, Capitain, O, Ramee Jean, F, Raoul Jean, L, Douillard, J-Y, Etienne Pierre, L, Cumin, I, Dupuis, O, Faroux, R, Coulon, M-A, Deguiral, P, Le Rol, A, Achour Nacr, E, Gorlaouen, A, Bouret, J-F, Marhuenda, F, Deniel Lagadec, D, Grude, F

Get full text

A large French multicenter retrospective series of T1-T2N0 vocal cords carcinomas treated with exclusive irradiation by Robert, A., Pointreau, Y., Janoray, G., Bardet, É., Fesneau, M., Garaud, P., Chapet, S., Lafond, C., Dupuis, O., Calais, G.

“…The main objective of this study was to evaluate the 5-year efficacy of exclusive laryngeal radiotherapy without node prophylactic irradiation for localized…”
Get full text

CEREBRAL OXYGENATION/PERFUSION, CARDIAC HEMODYNAMICS DURING EXERCISE AND COGNITIVE FUNCTIONS IN OBESE PATIENTS by Lapierre, G, Dupuis, O, Frazer, S, Bherer, L, Labelle, V, Juneau, M, Gremeaux, V, Gayda, M

Get full text

Assessment of forceps blade orientations during their placement using an instrumented childbirth simulator by Dupuis, O, Moreau, R, Pham, MT, Redarce, T

“…This paper aims to highlight the benefits of simulator training in obstetric manipulations such as forceps blade placement. The BirthSIM simulator is used to…”
Get full text

Implementing new technology in radiation oncology: The French agency for nuclear safety (ASN) report by Lartigau, É-F, Lisbona, A, Isambert, A, Cadot, P, Derreumaux, S, Dupuis, O, Gérard, J-P, Ledu, D, Mahé, M-A, Marchesi, V, Mazurier, J, De Oliveira, A, Phare, O, Aubert, B

“…In August 2013, the French nuclear safety agency (ASN) requested the permanent group of experts in radiation protection in medicine (GPMED) to propose…”
Get full text

Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial) by Zelek, L., Bugat, R., Cherqui, D., Ganem, G., Valleur, P., Guimbaud, R., Dupuis, O., Aziza, T., Fagniez, P. L., Auroux, J., Kobeiter, H., Tayar, C., Braud, A. C., Haddad, E., Piolot, A., Buyse, M., Piedbois, P.

“…Background: The purpose of this study was to evaluate the tolerance and efficacy of combining i.v. irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with…”
Get full text